---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-26-000038"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:37:11.680692+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akebia posts Q1 net loss of $9.1M; Vafseo revenue rises to $15.8M, patients up 60%

## Summary
- Net loss of $9.1M in Q1 2026 vs net income of $6.1M in Q1 2025; total revenues $53.5M, down from $57.3M.
- Vafseo net product revenue $15.8M (+31% YoY); patients on Vafseo increased 60% vs Q4 2025; prescribers up 28%.
- Auryxia net revenue $36.2M, down from $43.8M, with generic competition expected to expand in 2026.
- Cash $162.6M at March 31, 2026; company expects sufficient cash to fund operations for at least two years.
- Pipeline: praliciguat Phase 2 FSGS enrolling; AKB-097 basket study planned H2 2026; AKB-9090 Phase 1 initiated.

## SEC filing metadata
- accession: 0001517022-26-000038
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000038/0001517022-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000038/akba-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-26-000038
- JSON: https://secwatch.observer/filing/0001517022-26-000038.json
- Plain text: https://secwatch.observer/filing/0001517022-26-000038.txt

## Source-grounded claims
- claim_id: 2555a3d7b8fd9d70ba866736b0707934a15243e1
  claim: Akebia Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue $53.5 million.
  evidence_excerpt: Total revenues were $53.5 million in the first quarter of 2026 compared to $57.3 million in the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000038/0001517022-26-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.